[O3] Oral Session 3　Hematologic Malignancies
【E】

[O3-2] Parsaclisib in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL): Primary Analysis From CITADEL-203

^○Ryan C. Lynch¹, Abraham Avigdor^2,3, Matthew S. Mckinney⁴, Shankara Paneesha⁵, BjÖRn E. Wahlin⁶, John S. Hrom⁷, David Cunningham⁸, Nicholas Morley⁹, Miguel Canales¹⁰, Mariana Bastos-Oreiro¹¹, David Belada¹², Liliana Devizzi¹³, Fred Zheng¹⁴, Douglas J. Demarini¹⁴, Wei Jiang¹⁴, Marek Trněný¹⁵ (1.Seattle Cancer Care Alliance, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, 2.Sackler Faculty of Medicine, Tel Aviv University, 3.Institute of Hematology, Sheba Medical Center, 4.Duke Cancer Institute, 5.Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, 6.Karolinska Institutet, Department of Medicine, Huddinge, and Karolinska University Hospital, Unit for Hematology, 7.Forrest General Hospital and Hattiesburg Clinic, 8.Royal Marsden Hospital, NHS Foundation Trust, 9.Sheffield Teaching Hospital NHS Foundation Trust, 10.Hospital Universitario La Paz, 11.Hospital General Universitario Gregorio Marañón (IiSGM), 12.4th Department of Internal Medicine – Hematology, Charles University, Hospital and Faculty of Medicine, 13.Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 14.Incyte Corporation, 15.First Department of Medicine – Hematology, Charles University General Hospital)